Skip to main content

Adverse Events

Overcoming Resistance: Antibiotic Guidance for Multidrug-Resistant Febrile Neutropenia in Patients with Cancer
Sonya K. Kedzior, PharmD; YoungYoon Ham, PharmD; Joseph Bubalo, PharmD, BCOP, BCPS
Read More
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
Read More
Impact of Drug Repository Program in a Rural Oncology Clinic
Abstract #PM02
Read More
Evaluation of Treatment Abandonment and Delay with Anticancer Agents at an Outpatient Community Hospital Cancer Center Oral Chemotherapy Clinic: A Retrospective Cohort Analysis
Abstract #PM01
Read More
Evaluation of the Relationship between Hypoalbuminemia and Oral Anticancer Drug-Related Adverse Events in Adults with Solid Tumor Malignancies
Abstract #CT14
Read More
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
Abstract #CT07
Read More
Sitagliptin, a DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant
Read More
Meeting Highlights
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
Read More
Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan
Ekim Ekinci, PharmD, MS, BCOP; James E. Cox, PharmD, BCOP; Joe E. Ensor, PhD; Edward T. McLean, PharmD, BCOP; Carlos A. Ramos, MD; Premal D. Lulla, MD; Rammurti T. Kamble, MD; George Carrum, MD
Read More
Evaluation of Infusion-Related and Hypersensitivity Reactions to Chemotherapy Over a Decade at a Community Cancer Center
Sarah Maryon Hayes, PharmD, BCOP; Jeremy Whalen, PharmD, BCOP; Nick Schutz, PharmD; Joseph Levine, MD
Read More
Page 10 of 11
Results 91 - 100 of 109